Palbociclib-d8

Palbociclib-d8

• CAS Number: 1628752-83-9
• UNSPSC Description: Palbociclib-d8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].
• Target Antigen: CDK
• Type: Isotope-Labeled Compounds
• Related Pathways: Cell Cycle/DNA Damage
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Purity: 99.84
• Solubility: DMSO : 1 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 8.33 mg/mL (ultrasonic;warming;adjust pH to 3 with HCl;heat to 80°C)
• Smiles: O=C1N(C2=NC(NC3=NC=C(C=C3)N4C([2H])(C([2H])(NC([2H])(C4([2H])[2H])[2H])[2H])[2H])=NC=C2C(C)=C1C(C)=O)C5CCCC5
• Molecular Weight: 455.58
• References & Citations: [1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported